Related Experiment Video
Updated: Aug 15, 2025

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
An epidemiological evaluation of COVID-19 in La paz, Bolivia
Ryota Ito1, Masayuki Maeda2, Yumiko Takehara3
1Faculty of Foreign Studies, Department of Spanish & Latin American Studies, Nanzan University, Aichi, Japan.
Insights
COVID-19 prevalence in La Paz, Bolivia, was significantly higher than official reports, with over 63% of residents affected. Vaccination proved highly effective in reducing COVID-19 onset and mortality risk.
Area of Science:
- Epidemiology
- Public Health
- Infectious Diseases
Background:
- Bolivia has faced four major waves of COVID-19.
- Accurate COVID-19 epidemiology in Bolivia is poorly defined, hindering pandemic forecasting.
- Community-level prevalence, determinants, and vaccine effectiveness require investigation.
Purpose of the Study:
- To examine the community-level prevalence of COVID-19 in La Paz, Bolivia.
- To identify determinants of COVID-19 occurrence.
- To assess the effectiveness of COVID-19 vaccination.
Main Methods:
- A cross-sectional study was conducted in La Paz city.
- Data were collected from 2,775 individuals between March 2020 and February 2022.
- A structured questionnaire gathered information on COVID-19 morbidity, mortality, and vaccination status.
Main Results:
- The COVID-19 infection prevalence was 57.1%, with an additional 6.7% suspected cases, totaling 63.8%.
- The mortality rate was 2.9%.
- Vaccination significantly reduced the risk of COVID-19 onset and mortality (OR 0.037, p<0.001).
Conclusions:
- Actual COVID-19 prevalence in La Paz (63.8%) far exceeded official figures (7.5%).
- Vaccination played a crucial role in controlling the COVID-19 epidemic in Bolivia.
- Findings can inform future COVID-19 prevention strategies in Bolivia.
Introduction:
The Plurinational State of Bolivia (Bolivia) has experienced four major waves of coronavirus disease 2019 (COVID-19) so far. Although the ministry of health has been tracking morbidity and mortality through each wave, epidemiology of COVID-19 in Bolivia is not well defined, despite a need for more accurate measurement of the number of cases and deaths to allow for forecasting of the pandemic. This study examined prevalence of COVID-19 at community level, determinants of its occurrence and vaccine effectiveness.
Methods:
We conducted a cross-sectional study in La Paz city on 2,775 individuals between March 2020 and February 2022. A structured questionnaire was used to collect data on COVID-19 morbidity, mortality and vaccination status.
Results:
Of the 2,775 participants, 1,586 (57.1%) were infected with COVID-19, and 187 (6.7%) were suspected cases. The mortality rate was 2.9%. Sinopharm, Johnson & Johnson, Gamaleya, Pfizer-BioNtech, Moderna and AstraZeneka vaccines are in use, and all vaccines have demonstrated effectiveness in reducing the risk of onset. Risk for mortality was significantly lower in the vaccinated group with an odds ratio of 0.037 (95% confidential interval: 0.01-0.10, p-value: <0.001).
Conclusions:
Actual prevalence of COVID-19 in La Paz (the prevalence rate: 63.8%, including suspected case) was higher than that reported by the Ministry of Health and Sports in Bolivia (7.5%). In addition, vaccination has contributed significantly to the control of the COVID-19 epidemic in Bolivia. We believe that our report will be useful for COVID-19 prevention strategies in Bolivia for the future.
Related Concept Videos
Bias in Epidemiological Studies
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Causality in Epidemiology
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

